BG102784A - Synthetic hiv genes - Google Patents

Synthetic hiv genes

Info

Publication number
BG102784A
BG102784A BG102784A BG10278498A BG102784A BG 102784 A BG102784 A BG 102784A BG 102784 A BG102784 A BG 102784A BG 10278498 A BG10278498 A BG 10278498A BG 102784 A BG102784 A BG 102784A
Authority
BG
Bulgaria
Prior art keywords
synthetic
hiv genes
synthetic hiv
codons
genes
Prior art date
Application number
BG102784A
Other languages
Bulgarian (bg)
English (en)
Inventor
John SHIVER
Mary-Ellen Davies
Daniel FREED
Margaret Liu
Helen PERRY
Original Assignee
Merck & Co. Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9607293.9A external-priority patent/GB9607293D0/en
Application filed by Merck & Co. Inc. filed Critical Merck & Co. Inc.
Publication of BG102784A publication Critical patent/BG102784A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BG102784A 1996-02-22 1998-09-23 Synthetic hiv genes BG102784A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1208296P 1996-02-22 1996-02-22
GBGB9607293.9A GB9607293D0 (en) 1996-04-09 1996-04-09 Synthetic hiv env genes
PCT/US1997/002294 WO1997031115A2 (fr) 1996-02-22 1997-02-18 Genes synthetiques du vih

Publications (1)

Publication Number Publication Date
BG102784A true BG102784A (en) 1999-05-31

Family

ID=26309076

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102784A BG102784A (en) 1996-02-22 1998-09-23 Synthetic hiv genes

Country Status (27)

Country Link
EP (1) EP0904380B1 (fr)
JP (1) JP2000505299A (fr)
KR (1) KR19990087126A (fr)
CN (1) CN1216064A (fr)
AR (1) AR005930A1 (fr)
AT (1) ATE309366T1 (fr)
AU (1) AU729231B2 (fr)
BG (1) BG102784A (fr)
BR (1) BR9707672A (fr)
CO (1) CO4600706A1 (fr)
CZ (1) CZ266798A3 (fr)
DE (1) DE69734585T2 (fr)
EE (1) EE9800257A (fr)
ES (1) ES2251734T3 (fr)
HR (1) HRP970092A2 (fr)
HU (1) HUP9901112A3 (fr)
ID (1) ID16021A (fr)
IL (1) IL125547A0 (fr)
IS (1) IS4814A (fr)
NO (1) NO983876L (fr)
NZ (1) NZ331161A (fr)
PE (1) PE43298A1 (fr)
PL (1) PL328730A1 (fr)
SK (1) SK112998A3 (fr)
TR (1) TR199801615T2 (fr)
WO (1) WO1997031115A2 (fr)
YU (1) YU35498A (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6534312B1 (en) 1996-02-22 2003-03-18 Merck & Co., Inc. Vaccines comprising synthetic genes
CA2258568A1 (fr) * 1996-06-21 1997-12-24 Merck & Co., Inc. Vaccins comprenant des genes de synthese
US6696291B2 (en) 1997-02-07 2004-02-24 Merck & Co., Inc. Synthetic HIV gag genes
IL131131A0 (en) * 1997-02-07 2001-01-28 Merck & Co Inc Synthetic hiv gag genes
NZ338093A (en) 1997-04-04 2001-06-29 Patricia L Herman Methods and materials for making and using transgenic dicamba-degrading organisms
US7105724B2 (en) 1997-04-04 2006-09-12 Board Of Regents Of University Of Nebraska Methods and materials for making and using transgenic dicamba-degrading organisms
OA11520A (en) * 1997-10-20 2004-02-09 Genzyme Transgenics Corp Novel modified MSP-1 nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems.
AU2003200914B2 (en) * 1997-10-20 2007-02-01 Gtc Biotherapeutics, Inc. Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
US6924365B1 (en) 1998-09-29 2005-08-02 Transkaryotic Therapies, Inc. Optimized messenger RNA
EP1535995A1 (fr) * 1998-12-31 2005-06-01 Chiron Corporation Polynucléotides codant pour le polypeptide antigénique env du virus VIH de type C et leurs utilisations
EP1433851A3 (fr) * 1998-12-31 2004-10-13 Chiron Corporation Expression ameliorée de polypeptides HIV et production de particules de type viral
CA2360347C (fr) * 1998-12-31 2013-05-07 Chiron Corporation Expression amelioree de polypeptides hiv et production de particules de type viral
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
JP2003523721A (ja) 1998-12-31 2003-08-12 カイロン コーポレイション 抗原性ｈｉｖｃ型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用
US6395714B1 (en) 1999-02-24 2002-05-28 Aventis Pasteur Limited Expressing gp140 fragment of primary HIV-1 isolate
CA2369119A1 (fr) 1999-03-29 2000-05-25 Statens Serum Institut Methode de production d'une construction de sequence de nucleotides a base de codons optimises, pour un vaccin genetique contre le vih, a partir d'un isolat primaire et precoce duvih, et constructions de l'enveloppe synthetique bx08
US8647864B2 (en) 1999-04-14 2014-02-11 Novartis Ag Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
EP1200622A4 (fr) 1999-07-06 2004-12-22 Merck & Co Inc Vaccin contre le vih comprenant un adenovirus vehiculant le gene gag
EP2278022A3 (fr) 1999-11-01 2011-05-18 Novartis Vaccines and Diagnostics, Inc. Vecteurs d'expression, systèmes de transfection et procédé d'utilisation correspondant
WO2001045748A1 (fr) * 1999-12-22 2001-06-28 Merck & Co., Inc. Vaccins polynucleotidiques exprimant le gene pol du vih-1 a optimisation des codons et le gene pol du vih-1 modifie
GB0014288D0 (en) 2000-06-10 2000-08-02 Smithkline Beecham Biolog Vaccine
GB0017990D0 (en) 2000-07-21 2000-09-13 Glaxo Group Ltd Papilloma virus sequences
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
US6733994B2 (en) * 2000-10-04 2004-05-11 The Trustees Of The University Of Pennsylvania Highly expressible genes
KR20020059856A (ko) * 2001-01-08 2002-07-16 김철중 에이치아이브이 유사입자의 제조
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
EP1427826B1 (fr) * 2001-09-20 2011-04-20 Glaxo Group Limited Vaccins VIH-RT-nef-Gag à DNA avec codons optimisés
WO2005063286A1 (fr) 2003-12-23 2005-07-14 Arbor Vita Corporation Anticorps pour des souches oncogenes du hpv et leurs methodes d'utilisation
US7855326B2 (en) 2006-06-06 2010-12-21 Monsanto Technology Llc Methods for weed control using plants having dicamba-degrading enzymatic activity
US8754011B2 (en) 2006-10-16 2014-06-17 Monsanto Technology Llc Methods and compositions for improving plant health
US7838729B2 (en) 2007-02-26 2010-11-23 Monsanto Technology Llc Chloroplast transit peptides for efficient targeting of DMO and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ262582A (en) * 1993-01-26 1997-10-24 David B Weiner Compositions and methods for delivery of genetic material
DE69536091D1 (de) * 1994-01-27 2010-09-09 Univ Massachusetts Medical Immunisierung durch Impfung von DNS Transkriptionseinheit
US6630455B1 (en) * 1995-01-13 2003-10-07 Vanderbilt University Methods for inducing mucosal immune responses
JPH08198774A (ja) * 1995-01-20 1996-08-06 Terumo Corp Ｄｎａワクチン

Also Published As

Publication number Publication date
EE9800257A (et) 1999-02-15
YU35498A (sh) 1999-07-28
TR199801615T2 (xx) 1998-11-23
EP0904380A2 (fr) 1999-03-31
PL328730A1 (en) 1999-02-15
EP0904380B1 (fr) 2005-11-09
BR9707672A (pt) 1999-04-13
PE43298A1 (es) 1998-08-29
NO983876L (no) 1998-10-21
DE69734585T2 (de) 2006-08-10
CZ266798A3 (cs) 1999-03-17
CN1216064A (zh) 1999-05-05
AU2124697A (en) 1997-09-10
HUP9901112A2 (hu) 1999-07-28
ATE309366T1 (de) 2005-11-15
KR19990087126A (ko) 1999-12-15
CO4600706A1 (es) 1998-05-08
HRP970092A2 (en) 1998-04-30
AU729231B2 (en) 2001-01-25
IS4814A (is) 1998-07-30
ES2251734T3 (es) 2006-05-01
WO1997031115A3 (fr) 1997-10-09
AR005930A1 (es) 1999-07-21
NO983876D0 (no) 1998-08-21
HUP9901112A3 (en) 2001-06-28
NZ331161A (en) 2000-03-27
ID16021A (id) 1997-08-28
JP2000505299A (ja) 2000-05-09
DE69734585D1 (de) 2005-12-15
WO1997031115A2 (fr) 1997-08-28
IL125547A0 (en) 1999-03-12
SK112998A3 (en) 2000-04-10

Similar Documents

Publication Publication Date Title
BG102784A (en) Synthetic hiv genes
ZA956709B (en) Ionene polymers containing biologically-active anions
DE69534778D1 (en) Cathepsin-02-protease
BR9814404A (pt) " clonagem de expressão em fungos filamentosos "
IL131131A0 (en) Synthetic hiv gag genes
NZ335485A (en) Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
DK1009832T3 (da) Cytokin betegnet LERK-6
PT1212358E (pt) Genes sinteticos de papilomavirus humano
DE69413039D1 (de) Prostaglandin rezeptor fp und kodierende dns
WO1999004011A3 (fr) Antigenes du groupe o du vih-1 et leurs utilisations
MX9703364A (es) Peptidos capaces de unirse al dominio sh3 de la proteina gap, secuencias nucleotidicas que codifican para estos peptidos, su preparacion y su uso.
FI971276A (fi) Lerk-6:ksi nimetty sytokiini
ATE254109T1 (de) Neue polymerisierbare acylimidazolidinonmonomere
AU3711597A (en) A novel galanin receptor
ZA982009B (en) Isolated nucleic acid molecules encoding SSX family members and uses thereof.
HUP9901299A3 (en) New indications for the use as medicaments of multipotent parapox immunity inducers from attenuated, non-immunogenic pox viruses or parapox viruses
ES2048652A1 (es) Procedimientos de amplificacion de genoma para la deteccion e identificacion de secuencias genomicas relacionadas.
WO2001039786A3 (fr) Nouvelles utilisations des facteurs d'activation des macrophages suppresseurs
DE69838615D1 (de) ppGpp-SYNTHETASE UND EXPRESSIONSSYSTEME ZUR VERBESSERTEN HERSTELLUNG VON PROTEINEN
EP1757618A3 (fr) Proteines associées a l'angiogenese et acides nucleiques codant pour les dites proteines
ZA99445B (en) Isolated, polypeptides which bind to HLA-A29 molecules nucleic acid, the molecules encoding these, and uses thereof.
SE9604439D0 (sv) New receptor
Wohlman Plato's Invisible Cities
EA199900726A1 (ru) Синтетические hiv gag гены
IT8520282A0 (it) Procedimento per migliorare le proprieta' del cemento, e cemento cosi' ottenuto.